Colon‐targeted complement C5a<sub>1</sub> receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis
This novel colon-targeted formulation therefore offers a potent therapeutic strategy for translating C5a<sub>1</sub> receptor antagonists for IBD conditions such as ulcerative colitis.
Authors
- Andrew K. Whittaker (ORCID: https://orcid.org/0000-0002-1948-8355)
- Cedric S. Cui (ORCID: https://orcid.org/0000-0002-0534-027X)
- Titaya Lerskiatiphanich (ORCID: https://orcid.org/0000-0002-6153-313X)
- Felicity Y. Han (ORCID: https://orcid.org/0000-0001-7260-5832)
- Richard J. Clark (ORCID: https://orcid.org/0000-0002-6807-5426)
- Vinod Kumar (ORCID: https://orcid.org/0000-0002-7263-9917)
- Rabina Giri (ORCID: https://orcid.org/0000-0002-6712-6076)
- Xaria X. Li (ORCID: https://orcid.org/0000-0001-5924-2977)
- Trent M. Woodruff (ORCID: https://orcid.org/0000-0003-1382-911X)
- Jakob Begun (ORCID: https://orcid.org/0000-0001-5256-7672)
- John D. Lee (ORCID: https://orcid.org/0000-0002-9976-7396)
- Ning Liu (ORCID: https://orcid.org/0000-0002-5713-7900)
Institutions
- Translational Research Institute (AU)
- The University of Queensland (AU)
- Mater Research (AU)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-04-27
- DOI
- https://doi.org/10.1111/bph.70056
- Citations
- 4
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.19
Funders
- National Health and Medical Research Council